Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2026)

Revolution Medicines' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $289.6 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 82.6% year-over-year to $289.6 million in Q1 2026; TTM through Mar 2026 was $289.6 million, a 82.6% increase from a year earlier, with the FY2025 full-year figure at $290.4 million, up 77.18% from the prior year.
• Total Current Liabilities held at $289.6 million in Q1 2026 per RVMD's latest filing, from $290.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $290.4 million in Q4 2025 and bottomed at $54.6 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $105.3 million (2024), against an average of $133.0 million.
• Biggest YoY gain for Total Current Liabilities was 132.08% in 2023; the steepest drop was 4.91% in 2023.
• Year by year, Total Current Liabilities stood at $62.0 million in 2022, then soared by 132.08% to $143.9 million in 2023, then advanced by 13.95% to $163.9 million in 2024, then jumped by 77.18% to $290.4 million in 2025, then dropped by 0.28% to $289.6 million in 2026.
• Per Business Quant, the three latest RVMD Total Current Liabilities figures stand at $289.6 million (Q1 2026), $290.4 million (Q4 2025), and $245.6 million (Q3 2025).